Management

Shin Dong-bin Sells 42 Billion Won Worth of LOTTE SHOPPING CO., LTD. Shares… “To Secure Liquidity”

Disclosure of Transaction Plan Reports Under the Capital Markets Act

KYUNG GYEYOUNG
2026-07-22 17:02:52
[Edaily Reporter KYUNG GYEYOUNG ] Shin Dong-bin, Chairman of Lotte Group, has decided to sell a portion of his stake in LOTTE SHOPPING CO., LTD. valued at 42 billion won.

LOTTE SHOPPING CO., LTD.(023530) In a transaction plan report filed on the 22nd, Chairman Shin announced his intention to sell 324,100 shares of Lotte Shopping between August 21 and September 18. Based on the previous day’s closing price of 130,400 won per share, this amounts to 42.26264 billion won.

Although the plan is to sell on the open market, he also stated that, depending on market supply and demand conditions, he may conduct a block trade outside regular trading hours.

Regarding this sale plan, Chairman Shin explained in the report that it is “for the purpose of securing cash liquidity.”

Chairman Shin’s stake in LOTTE SHOPPING CO., LTD. will decrease by 1.15 percentage points, from 10.23% to 9.08%. However, since affiliates and related parties—including Lotte Department Store ( Lotte Corporation(004990) ) with 40.0% and Lotte Hotel with 8.86%—hold approximately 60% of the shares, the move is not expected to affect the company’s corporate governance structure.

This is a disclosure required under the Capital Markets Act. Under the Act, executives or major shareholders of listed companies are required to report their trading plans at least 30 days prior to the start of trading when trading shares representing 1% or more of the total issued shares or worth 5 billion won or more.

Shin Dong-bin, Chairman of Lotte Group. (Photo courtesy of Lotte)

Economy

Corporation

IT·Science

Economy

SK Hanik Surprised by Rumors of a '16 Trillion Won' Special Dividend… "Additional Shareholder Returns to Be Announced on the 28th"

SK hynix announced that it is reviewing various shareholder return measures, including the possibility of a special dividend using the capital gains from its investment in Japanese semiconductor compa…
2026-10-26 10:32:59

Corporation

[ESMO 2026] Ok Chan-young, Director of the Ligacem Center: “LCB02A Expected to Be Effective Even in Patients with Low Claudin 18.2 Expression”

“LCB02A uses exatecan as its payload. Drugs in the exatecan class have a bystander effect that allows them to attack surrounding cancer cells, and this effect is expected to be further enhanced throug…
2026-10-26 11:22:02

IT·Science

DongKook Life Science Co., Ltd. Plans to Change Company Name to ‘DK Ruonics’… to Expand New Drug and CMO Businesses

#DongKook Life Science Co., Ltd. is moving forward with a plan to change its company name to “DK Luonix.” Through this change, the company plans to expand its business scope from its current focus on …
2026-10-26 13:42:02